Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Respirerx Pharmaceuticals Inc (OP: RSPI )

0.0009 UNCHANGED
Streaming Delayed Price Updated: 9:40 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 967,542
Open 0.0009
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0009
Today's Range 0.0009 - 0.0009
52wk Range 0.0006 - 0.0191
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRx
RespireRx Pharmaceuticals Inc. (OTCPK:RSPI), focused on the discovery and development of treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd, an unlisted... 
Via Benzinga
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
From RespireRX Pharmaceuticals Inc.
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
-43.75%
-43.75%
6 Month
+12.50%
+12.50%
1 Year
-70.97%
-70.97%

More News

Read More
RespireRx Signs LOI With Australian CRO For Dronabinol Development For Obstructive Sleep Apnea
Via Benzinga
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
From RespireRX Pharmaceuticals Inc.
Via GlobeNewswire
RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4
From RespireRX Pharmaceuticals Inc.
Via GlobeNewswire
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
From RespireRX Pharmaceuticals Inc.
Via GlobeNewswire
RespireRx Pharmaceuticals Files Patent: Claims To Improve Solubility & Bioavailability Of Cannabinoids
Via Benzinga
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.